"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

While we have made progress with FDA approval of two treatments that can slow cognitive decline in early-stage Alzheimer’s ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...

Scientists have created a game-changing 'Alzheimer's in a dish' model that allows for faster and more accurate testing of ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Greeny, A, Nair, A, Sadanandan, P, Satarker, S, Famurewa, AC and Nampoothiri, M (2024) Epigenetic Alterations in Alzheimer's ...

Alzheimer’s disease remains one of the most pressing challenges in modern medicine, ranking as a leading cause of death ...

EXCLUSIVE: UCL researchers argue that loss of brain volume may in fact be a sign that the treatments are working.

New research has established a link between a specific type of body fat and brain proteins that are hallmarks of Alzheimer's ...